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Paired receptors are families of membrane proteins containing similar extracellular regions but differing in
their potential for signaling with one type able to give inhibitory signals and the other activating. Inhibitory
receptors could be good targets for pathogens to restrict immune responses against them. Here we suggest
that activating members may have evolved to counterbalance pathogens utilizing the inhibitory pathway.
Thus, if a pathogen utilizes any part of the inhibitory receptor to downregulate responses against itself, it
may, because of similarities in structure, also bind the activating receptor and give an opposing signal.
We evaluate recent structural data on SIRPa (signal regulatory protein) and LILRB1 (leukocyte immunoglob-
ulin-like receptor subfamily B member 1) showing evidence of pathogen pressure in nonligand-binding
regions of these receptors together with data on pathogen binding to PIRs (paired Ig-like receptors) to
provide support for this theory.Introduction
The term ‘‘paired receptor’’ is commonly
used to describe families of membrane re-
ceptors that have very similar extracellular
regions but different transmembrane and
cytoplasmic regions. Indeed, the latter are
so different that they can give opposite
signals (Lanier, 2001). One type can give
inhibition through immunoreceptor tyro-
sine-based inhibition motifs (ITIM) in the
cytoplasmic region. The other can activate
through signaling proteins like DAP12
that contain immunoreceptor tyrosine-
based activating motifs (ITAM) that are as-
sociated with the receptor via interactions
through their transmembrane regions
(Dietrich et al., 2000; Lanier, 2005). Paired
receptors are often expressed by NK
cells, others are restricted to myeloid
cells, but some are found on other leuko-
cytes and also neuronal cells (Lanier,
2005). Paired receptors include SIRP,
CD200R, KIR, Ly49, CD300, DCIR, PIR,
PILR, TREM, LILR, Siglecs, etc., with many
alternative names summarized in Yamada
and McVicar (2008).
If the outcomes of engagement of
paired receptors are so different and the
extracellular regions so similar, then if
their ligands are the same, one gets the
confusing situation of two outcomes for
the presence of the same ligand. Often
a cell will express both inhibitory and acti-
vating members. In most cases, ligands
for the inhibitory receptors are known
and the activating receptors bind more
weakly or not at all with quantitativedata available for several pairs, e.g.,
CD94-NKG2 (Vales-Gomez et al., 1999),
CD200R (Hatherley et al., 2005), SIRP
(Barclay and Brown, 2006), and PILR
(Tabata et al., 2008).
The inhibitory receptors generally inter-
act with self proteins and provide a mech-
anism to limit cell activity as shown in NK
cells (Lanier, 2005) and myeloid cells (Bar-
clay and Brown, 2006). The roles of the
activating receptors are less clear, espe-
cially those on cells other than NK cells.
Many of the paired receptor families are
evolving rapidly, indicative of pressure
from pathogens (Vilches and Parham,
2002). Although paired receptors on NK
cells are heavily involved in the recogni-
tion of pathogen-infected cells, others
such as CD200R and SIRPa are involved
in the control of myeloid cell activity
(Barclay and Brown, 2006; Foster-Cuevas
et al., 2004). How might pathogens drive
this evolution? The targeting by patho-
gens of inhibitory receptors involved in
cell regulation is clearly a sensible strat-
egy from the pathogen’s point of view.
We suggest a mechanism for paired
receptors by which activating receptors
have evolved to interact with those patho-
gens that target inhibitory receptors i.e.,
the activating receptors act as a counter-
balance. Thus for paired receptors such
as SIRP, if a pathogen targets the inhibi-
tory receptor, it is probable that the
pathogen also binds the activating recep-
tor because of its similar extracellular
regions, and hence nullifies the inhibitoryImmunity 29,effect (Hatherley et al., 2008). We discuss
recent structural data on the SIRP family
and LILRB1 together with pathogen bind-
ing data for other paired receptors with
respect to this model.
The Structure of SIRPa
SIRPa (also known as SHPS-1, BIT,
CD172a [van den Berg et al., 2005]) is
the inhibitory member of the SIRP family,
SIRPb is the activating form associating
with DAP12, and SIRPg is a third form
that does not signal (Barclay and Brown,
2006). The N-terminal immunoglobulin
superfamily (IgSF) domain of SIRPa (d1)
interacts with the single IgSF domain of
CD47, a widely distributed membrane
protein. X-ray crystallography structures
have been determined for the SIRP family
members and CD47 (Hatherley et al., 2007,
2008; Nakaishi et al., 2008). SIRPa binds
CD47 through loops in a manner analo-
gous to binding of antigen by immunoglob-
ulins and the T cell receptor, and the failure
of SIRPb to bind to CD47 is due to subtle
differences in these loops (Hatherley et al.,
2008).
Polymorphisms in Human SIRPa
and Ligand Binding
SIRPa shows extensive polymorphism
with 10–12 amino acid differences in
domain 1 but only 0–2 differences in
domains 2 and 3 between three mouse
strains (Sano et al., 1999) and even more
differences between the NOR (non-obese
resistant) and NOD (non-obese diabetic)November 14, 2008 ª2008 Elsevier Inc. 675
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(A) Alignments of the amino acid sequences of domain 1 of the two commonly studied SIRPa sequences
(accession numbers CAA71403 and NP_542970 for sequences 1 and 2, respectively) together with
polymorphisms identified in Takenaka et al. (2007). The positions of polymorphic residues are indicated
by giving the residue for each sequence and indicating those that differ from SIRPa (1) by green or for those
different from either SIRPa (1) or SIRPa (2) by magenta. The residues that form contacts with CD47 are
highlighted in red and the positions of the beta strands and one helical region are shown above the
alignment.
(B) The positions of the polymorphic residues are mapped onto the SIRPa domain 1-CD47 extracellular
domain cocrystal structure (Hatherley et al., 2008). The side chains of the polymorphic residues are
indicated with spheres in green and magenta to distinguish the polymorphic residues as in (A).mice (20 differences in domain 1 [Taken-
aka et al., 2007]). In humans, 37 different
individuals showed 9 different SIRPa
domain 1 sequences (Figure 1; Takenaka
et al., 2007), making this one of the most
polymorphic genes in the immune system
after MHC and KIR antigens (Vilches and
Parham, 2002). In contrast, SIRPb and
SIRPg lack extensive polymorphism in676 Immunity 29, November 14, 2008 ª2008domain 1 and the two alleles of SIRPb
have extensive differences throughout
the sequence. Most researchers studying
SIRPa have used one or other of two se-
quences (1 and 2 in Figure 1A). We have
shown that both proteins bind CD47 with
the same affinity (KD = 1 mM [Hatherley
et al., 2008] and unpublished data). The
majority (14 out of 17) of the polymorphicElsevier Inc.residues in SIRPa d1 are strikingly distant
from the contact site for CD47 (Figure 1A).
However, the three residues near the
contact site are unlikely to affect binding
because they are present in one or other
of the two sequences that bind CD47
equally. The five residues not in either of
the two standard sequences are distant
from the binding site (shown in magenta
in Figures 1A and 1B). Given this and the
similarity of structures between the SIRPs
away from the binding site (see Hatherley
et al., 2008) and the failure of mutants
outside of the binding site to affect CD47
binding (Hatherley et al., 2007; Liu et al.,
2007), it is unlikely that the polymor-
phisms in human SIRPa will markedly
affect binding to CD47. CD47 itself lacks
extensive polymorphisms.
So what is driving the extensive SIRPa
d1 polymorphism? In both human and
mouse SIRPa d1 (see above), the majority
of polymorphisms are nonsynonomous
(Sano et al., 1999; ENSEMBL database),
indicating selective pressure. The side
chains of the polymorphic residue (16 out
of 17) are out-pointing and hence are
likely to be involved in interactions with
other molecules, whereas in-pointing res-
idues might be expected to have affects
on the folding of the domain. This is con-
sistent with evolutionary pressure through
interactions in this region. One possibility
is that these variants have been selected
not to react with particular pathogens
(i.e., avoiding downregulation of the
myeloid cell). Another comparable exam-
ple is the Nkrp1 lectin-like paired receptor
where the receptor but not the ligand
shows extensive polymorphism, and in-
deed it has recently been suggested this
is to avoid virus decoys targeting this
receptor (Carlyle et al., 2008). Thus, two
mechanisms are involved in avoiding
downregulation of activity—a high degree
of polymorphism in the inhibitory receptor
together with evolution of an activating re-
ceptor. One important concept is that the
pathogen does not necessarily need to
bind to the ligand binding site or indeed,
domain, to perturb the SIRPa and give
a signal—thus the sequence conservation
in the remainder of the extracellular region
is relevant (there is about 90% sequence
identity between the extracellular regions
of SIRPa, SIRPb, and SIRPg) (Figure 2).
There are no binding data for pathogens
to SIRPs but there are data for other
paired receptors (see below).
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Receptors
The concept that pathogens could bind
paired receptors has been established
with extensive functional data available
for the Ly49 NK receptors found in mice.
Resistance of B6 mice to mouse cyto-
megalovirus (mCMV) was found to be
conferred by the expression of Ly49H,
an activating receptor that binds to the
mCMV MHC-like protein m157. This m157
protein also binds the inhibitory Ly49I
receptor found in a susceptible mouse
strain (129) but does not bind the Ly49I re-
ceptor found in B6 mice (Arase et al., 2002;
Cheng et al., 2008; Smith et al., 2002).
Arase et al. (2002) suggested that whereas
the inhibitory receptors have evolved for
immunoregulation and preventing autoim-
munity, the activating receptor may have
evolved to recognize pathogen encoded
ligands. Given that pathogens evolve
faster than hosts, one might imagine that
the pathogen could easily evade these
activating receptors. Our suggestion dis-
cussed above (that pathogens might bind
both types of paired receptors and the ac-
tivating receptors act as a counterbalance)
would fit with the data in this case and
provide a general rationale for at least
some paired receptors. With regard to
Ly49, genetic divergence has led to strains
with either inhibitory or activating recep-
tors giving dramatic functional differences.
A variety of bacterial strains can bind
both the inhibitory mouse paired Ig-like
receptor (PIR-B) and at least one activat-
ing counterpart (PIR-A1) (Nakayama et al.,
2007); a different repertoire of bacteria
binds PIR-B (inhibitory) orthologs in
humans, namely leukocyte immunoglob-
ulin-like receptor subfamily B1 (LILRB1)
and LILRB3 (or ILT2 and ILT5) (Nakayama
et al., 2007). For the LILRB1, it seems
likely that the bacterial binding site is dis-
tinct from the ligand binding as indicated
by the fact that monoclonal antibody can
block the former and not affect the latter
(Nakayama et al., 2007). Another example
of pathogen binding is the involvement
of the inhibitory receptor PILRa in the up-
take of herpes simplex virus (Satoh et al.,
2008); however, no data were given on the
activating counterpart.
Evolution of Paired Receptors
There are data indicating the fast evolu-
tion of paired receptors both in terms of
gene numbers and sequence diversity.Although the evolution of KIRs (killer cell
immunoglobulin-like receptor) is tied to
MHC class I (the ligand) divergence
(Vilches and Parham, 2002), recent data
on the LILRB1 family support the concept
that evolutionary pressures may act on
sites other than the ligand binding as sug-
gested above for SIRPa. The N-terminal
two IgSF domains of LILRB1 form a bind-
ing site for MHC class I antigens. LILRB1,
like SIRPa, is polymorphic and 4 out of the
5 amino differences are in the ligand-
binding domains; three of these have no
affect on ligand binding affinity as tested
with a variety of MHC class I ligands and
the polymorphic residues are shown by
X-ray crystallography to be outside the
binding site (Kuroki et al., 2005). This
parallels the observation discussed
above for the SIRPs where there is evi-
dence for pressure of change in the inhib-
itory receptor away from the ligand
Figure 2. Sites Distant from Ligand-Binding
Regions of Inhibitory Receptors Are
Attractive Targets for Pathogens
The cartoon shows SIRPa (inhibitory) together with
its ligand CD47 with its binding face indicated in
red. The arrows indicate how pathogens might
target the regions of SIRPa not involved in CD47
binding, and then react with equivalent sites in
the activating SIRPb. N-linked glycosylation sites
are shown in black but the area covered by carbo-
hydrate would be much larger in 3D (Barclay et al.,
1997). The close proximity of the membranes in
immunological synapses when SIRPa engages
CD47 would also hinder access by pathogens.Immunity 29,binding site and in support of the counter-
balance theory.
It is likely that activating receptors
evolved from the inhibitory receptor and
they show much shorter half lives in evolu-
tion with greater variation in gene numbers
(Abi-Rached and Parham, 2005; Carlyle
et al., 2008; Vilches and Parham, 2002;
Wilson et al., 2006). The advantage of
greater numbers of activating receptors in
protecting against more pathogens is bal-
anced by greater risks for autoimmunity.
Another safeguard against unwanted
membrane receptor signaling may be
the utilization of synapse-like structures.
It is notable how many receptors including
many paired receptors are likely to span
around four IgSF domains compatible
with these interactions occurring at an
immunological synapse (Barclay and
Brown, 2006; Tsai and Discher, 2008;
Wright et al., 2000). If an inhibitory recep-
tor is active only in the immunological
synapse, for instance because of the
close proximity of other receptors and
kinases to ensure phosphorylation of the
cytoplasmic region, then it is likely to be
inaccessible to pathogens that would be
excluded from the immunological syn-
apse because of their size. However,
once a virus has infected a cell, virally
encoded proteins can be synthesized
and reach the surface and subvert
immune responses against the infected
cell. This appears to be the case in Kapo-
si’s sarcoma virus that has acquired
a CD200 homolog that can mimic the
host protein by interacting with the inhibi-
tory CD200R to downregulate macro-
phage activity (Foster-Cuevas et al.,
2004). Nevertheless, for initial virus infec-
tions and bacterial infections, the immu-
nological synapse may have a general,
underappreciated role to prevent subver-
sion of receptors once they have been ac-
tivated in this specialized contact region.
Conclusion
The theory that the activating partner of
a paired receptor might act as a counter-
balance to pathogens that are utilizing the
inhibitory receptor is strengthened by
three sets of recent data: first, structural
data on SIRP and LILRB1 recognition
establish the basis of ligand binding; sec-
ond, genetic studies on SIRPs and other
paired receptors reveal the extent of poly-
morphisms outside of the ligand binding
domain, indicating evolutionary pressureNovember 14, 2008 ª2008 Elsevier Inc. 677
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concept that pathogens might bind
regions outside the ligand binding area is
strengthened by recent data showing
direct binding of pathogens to paired
receptors. The prevalence of paired
receptors on myeloid cells would fit with
involvement of pathogen recognition
given that cells of the innate system will
be the first line of attack against patho-
gens. Many paired receptors may use
the activating receptor as a counterbal-
ance in this way. In the counterbalance
model, the pathogen may evolve to bind
the inhibitory receptor but have to accept
the down side of hitting the activating
receptor. It is notable that the number of
activating receptors seems to vary in indi-
viduals (and rodent strains) and obviously
a particular selection of inhibitory and/or
activating members may be adventitious
in the continuous battle between patho-
gen and host as observed with the Ly49
discussed above.
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